000			02069 a2200541 4500
005			20250518085339.0
264		0	_c20201030
008			202010s 0 0 eng d
022			_a1095-6859
024	7		_a10.1016/j.ygyno.2020.01.037 _2doi
040			_aNLM _beng _cNLM
100	1		_aO'Malley, David M
245	0	0	_aPhase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. _h[electronic resource]
260			_bGynecologic oncology _c05 2020
300			_a379-385 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal, Humanized _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBevacizumab _xadministration & dosage
650	0	4	_aCarcinoma, Ovarian Epithelial _xdrug therapy
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aFemale
650	0	4	_aFolate Receptor 1 _ximmunology
650	0	4	_aHumans
650	0	4	_aImmunoconjugates _xadministration & dosage
650	0	4	_aMaytansine _xadministration & dosage
650	0	4	_aMiddle Aged
650	0	4	_aOrganoplatinum Compounds _xpharmacology
650	0	4	_aOvarian Neoplasms _xdrug therapy
650	0	4	_aProgression-Free Survival
700	1		_aMatulonis, Ursula A
700	1		_aBirrer, Michael J
700	1		_aCastro, Cesar M
700	1		_aGilbert, Lucy
700	1		_aVergote, Ignace
700	1		_aMartin, Lainie P
700	1		_aMantia-Smaldone, Gina M
700	1		_aMartin, Antonio González
700	1		_aBratos, Raquel
700	1		_aPenson, Richard T
700	1		_aMalek, Karim
700	1		_aMoore, Kathleen N
773	0		_tGynecologic oncology _gvol. 157 _gno. 2 _gp. 379-385
856	4	0	_uhttps://doi.org/10.1016/j.ygyno.2020.01.037 _zAvailable from publisher's website
999			_c30657324 _d30657324